Sun Pharmaceuticals is the largest pharmaceutical company from India and the fifth largest specialty generic company in the world. It has capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets, and capsules. Its businesses include producing generics, branded generics, speciality, over the counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates in the full range of dosage forms. It also produces specialty APIs. In FY19, US formulations contributed the most to company’s sales with 37%, followed by India branded formulations at 26%.
Company Website: www.sunpharma.com
Sun Pharma – Reaching People. Touching Lives.
| 2020 | Sun Pharma announced five-year sustained efficacy and safety results for ILUMYA in patients with moderate-to-severe plaque psoriasis |
| 2019 | Sun Pharma and AstraZeneca entered into a license agreement for novel oncology products in China Sun Pharma’s arm, Sun Pharmaceutical Industries, acquired its remaining 3.04% stake in PJSC Biosintez, Russia Sun Pharma and China Medical System Holdings entered into licensing agreement for generic products in Mainland China |
| 2018 | Sun Pharma to acquire Pola Pharma in Japan |
| 2018 | Sales of Rs 27,956 crore (US$ 4 billion) in FY18; Announced acquisition of US-based speciality pharmaceutical company Avenue Therapeutics for Rs 1502.635 crore (US$ 215 million) |
| 2017 | Agreement signed with National Institute of Virology, India to fight Zika, Chikungunya and Dengue |
| 2013 | Became world’s fifth largest specialty generic pharmaceutical company with acquisition of Ranbaxy |
| 2000 | Acquired Pradeep Drug Company |
| 1997 | First international acquisition with Caraco Pharmaceutical Laboratories, USA |
| 1996 | Sales network expanded across 24 countries |
| 1994 | Launched initial public offer (IPO) |
| 1989 | Introduced gastroenterology products in India |
| 1983 | Established with a portfolio of five psychiatry products |